Douglas Roblin to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Douglas Roblin has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
0.302
-
Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010 Apr; 25(4):326-33.
Score: 0.084
-
Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates. Pharmacoepidemiol Drug Saf. 2010 Jan; 19(1):19-25.
Score: 0.084
-
Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007 Jan; 16(1):55-64.
Score: 0.068
-
Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin-converting enzyme inhibitor therapy. Pharmacoepidemiol Drug Saf. 2021 12; 30(12):1630-1634.
Score: 0.047
-
Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf. 2008 Mar; 17(3):240-7.
Score: 0.018